(RTTNews) - Thursday, Merck & Co., Inc. (MRK) announced a research collaboration with Isomorphic Labs, an AI-first drug design and development company, to discover therapeutic small molecule candidates against an oncology target of strategic importance.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.
